For the prevention of and response to diversion (i.e. selling or sharing of medications) or misuse (i.e. taking medication in a manner other than prescribed) of medications to treat opioid use disorder.
A Protocol using empirically-supported behavioral treatments for people with psychoactive stimulant use disorders. There are manuals for healthcare professionals who provide treatment services for individuals with psychoactive substance use disorder (PSUD) and for patients who are entering PSUD treatment.
This paper offers principle and recommendations for remediating the impacts of the rising rates of drugs adulterated or laced with fentanyl.
The slides from this informative webinar will aid drug court team members in tracking treatment progress and ensuring that participants adhere to medication in addiction treatment. jointly sponsored by the National Association of Drug Court Professionals and the American Society of Addiction Medicine, this webinar was designed especially for judges, coordinators, prosecutors, defense attorneys, supervision officers, case managers, and other team members who refer, monitor, or otherwise support behavioral health treatment in drug courts.
Describes strategies to help reduce the potential for misuse or diversion of medication for SUD treatment.
Provides facts about the benefits of using PDMPs for prescribers, pharmacists, patients, and regulatory and law enforcement agencies.
Provides guidance on the use of buprenorphine among a number of topics, including physiology and pharmacology of opioids, opioid addiction, and buprenorphine treatment; screening and assessment of OUDs; protocols for buprenorphine treatment; management of special populations; and policies and procedures related to DATA 2000.
Reviews three FDA-approved medications for OUD treatment (methadone, naltrexone, and buprenorphine) and the other strategies and services needed to support people in recovery.
Email Updates